TY - JOUR
T1 - Biological markers in breast carcinoma—clinical correlations with pseudouridine, n2,N2‐dimethylguanosine, and 1‐methylinosine
AU - Tormey, Douglass C.
AU - Waalkes, T. Phillip
AU - Gehrke, Charles W.
PY - 1980/7
Y1 - 1980/7
N2 - Urinary levels of the minor nucleosides, pseudouridine (Ψ), N2, N2‐dimethylguanosine (m22G), and 1‐methylinosine (m1I), were investigated in patients with breast carcinoma. Elevated levels of Ψ were observed in 27/131 (20.6%) patients with metastatic disease, 1/14 (7.1%) preoperative patients, and 1/28 (3.6%) postoperative N+ patients. Elevated levels of m22G and M1I were observed, respectively, in 46/131 (35.1%) and 27/131 (20.6%) patients with metastatic disease, 3/14 (21.4%), and 0/14 preoperative patients, and 6/28 (21.4%) and 2/28 (7.1%) postoperative N+ patients. There was no correlation between nucleoside levels and involvement of specific organ sites with metastatic disease, nor with chemotherapy response rate or time to treatment failure. During the treatment of metastatic disease there was a tendency for elevated pretherapy Ψ levels to decrease with attainment of a response and, if the levels subsequently rose, to be associated with treatment failure. However, increasing levels of m22G and m1I occurred with both response and disease progression. These results suggest that routine measurement of the level of the urinary nucleosides would be of limited value for following the disease course in patients with breast cancer.
AB - Urinary levels of the minor nucleosides, pseudouridine (Ψ), N2, N2‐dimethylguanosine (m22G), and 1‐methylinosine (m1I), were investigated in patients with breast carcinoma. Elevated levels of Ψ were observed in 27/131 (20.6%) patients with metastatic disease, 1/14 (7.1%) preoperative patients, and 1/28 (3.6%) postoperative N+ patients. Elevated levels of m22G and M1I were observed, respectively, in 46/131 (35.1%) and 27/131 (20.6%) patients with metastatic disease, 3/14 (21.4%), and 0/14 preoperative patients, and 6/28 (21.4%) and 2/28 (7.1%) postoperative N+ patients. There was no correlation between nucleoside levels and involvement of specific organ sites with metastatic disease, nor with chemotherapy response rate or time to treatment failure. During the treatment of metastatic disease there was a tendency for elevated pretherapy Ψ levels to decrease with attainment of a response and, if the levels subsequently rose, to be associated with treatment failure. However, increasing levels of m22G and m1I occurred with both response and disease progression. These results suggest that routine measurement of the level of the urinary nucleosides would be of limited value for following the disease course in patients with breast cancer.
KW - 1‐methylinosine
KW - N,N‐dimethylguanosine
KW - breast cancer
KW - nucleosides
KW - pseudouridine
UR - http://www.scopus.com/inward/record.url?scp=0018888909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018888909&partnerID=8YFLogxK
U2 - 10.1002/jso.2930140313
DO - 10.1002/jso.2930140313
M3 - Article
C2 - 7392649
AN - SCOPUS:0018888909
SN - 0022-4790
VL - 14
SP - 267
EP - 273
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 3
ER -